The FDA is under scrutiny regarding safety concerns related to the drug ELEVIDYS, which involves Sarepta Therapeutics.
14 reports, 8 independent
Updated Aug 25
Gone quiet
Reached 8 outlets in its first 24 hours
- Reports
- 14
- Developments
- 4
- Repetition
- 71%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is under scrutiny regarding safety concerns related to the drug ELEVIDYS, which involves Sarepta Therapeutics.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA scrutiny over ELEVIDYS safety concerns involving Sarepta Therapeutics.1 source
FDA requested Sarepta halt shipments of Elevidys due to safety concerns.1 source
FDA orders Sarepta to halt drug shipments due to safety concerns.1 source
- Investigation launched into Sarepta drug following patient deaths.
Keep exploring
The entities involved
- FDA
-
Sarepta Therapeutics
biopharmaceutical company
Nothing else this week.
Related events
- Anavex Life Sciences submitted data for FDA discussions and received scientific advice from the EMA.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- Experimental therapies require approval from the FDA.
- FDA safety warnings have been issued, causing caution among clinicians.
- The FDA has questioned promotional materials related to an investigational drug from Alar Pharmaceuticals.
Coverage
Newest first; wire copies grouped- Simply Wall St.Sarepta Therapeutics (SRPT): Assessing Valuation After Lawsuits and FDA Scrutiny Over ELEVIDYS Safety Concerns If you have been watching Sarepta Therapeutics (SRPT), this week's headlines have probab
- BioPharma DiveSarepta pushes off debt payments in bid to regain financial footing This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Di
- BloombergHow the Moms and Dads of Patients Won Sarepta’s Drug a Reprieve (Bloomberg) -- The parents leaped into action as soon as health officials asked Sarepta Therapeutics Inc. to stop selling an expensive
- BioPharma DiveSarepta sells Arrowhead shares as partnership, debt payments loom This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive
- Pharma VoiceAs gene therapies falter on the market, this biopharma is aiming to defy the odds This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily P
- BioPharma DiveElevidys sales weaken; Neumora gets into obesity This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Toda
- Business WireSarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union Partner Roche will continue its dialogue with the European Medicines Agency to explore a potential path forw
- Insider MonkeyArrowhead Pharma (ARWR) Shares Dragged by Sarepta Concerns We recently published 10 Big Names Get Slammed. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the biggest losers on Monday. Arrowh
- BenzingaSarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys The ground shook for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) last week as the U.S. Food and Drug Administration (F
- BioPharma Dive5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Div
- Yahoo FinanceSarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug Sarepta Therapeutics' (SRPT) stock continued to sink Monday, down about 5% in early trade, following a r
- Business WireSarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label – After strategic review, Sarep
- Unknown outlet
- Unknown outlet